Royal Bank Of Canada Forecasts Strong Price Appreciation for Definium Therapeutics (NASDAQ:DFTX) Stock

Key Points

• Royal Bank of Canada raised its price target for Definium Therapeutics from $57 to $66 and maintained an “outperform” rating, implying 48.92% potential upside. The analyst consensus remains “Buy,” with an average target of $61.46.
• DFTX shares rose 3.6% to $44.32, near their 52-week high of $49.70, but the company reported a quarterly loss of $1.44 per share—well below the $0.55 consensus estimate.
• Several analysts also increased their targets, including Wells Fargo to $72 and Piper Sandler to $75, while insiders sold 48,096 shares worth approximately $2.17 million over the past three months.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) had its price target boosted by equities researchers at Royal Bank Of Canada from $57.00 to $66.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Royal Bank Of Canada's price target points to a potential upside of 48.92% from the stock's current price.

A number of other equities research analysts have also commented on the stock. Citigroup restated a "buy" rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Needham & Company LLC upped their target price on shares of Definium Therapeutics from $50.00 to $66.00 and gave the stock a "buy" rating in a research note on Wednesday. Piper Sandler reiterated an "overweight" rating and set a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a report on Friday, August 7th. Canaccord Genuity Group set a $64.00 price target on Definium Therapeutics in a research note on Thursday. Finally, Wells Fargo & Company boosted their price target on Definium Therapeutics from $68.00 to $72.00 and gave the company an "overweight" rating in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Definium Therapeutics has a consensus rating of "Buy" and an average price target of $61.46.

Definium Therapeutics Stock Up 3.6%

Shares of DFTX traded up $1.53 on Thursday, hitting $44.32. The company's stock had a trading volume of 817,234 shares, compared to its average volume of 2,289,230. The firm's fifty day moving average price is $39.06 and its 200-day moving average price is $26.52. Definium Therapeutics has a fifty-two week low of $8.70 and a fifty-two week high of $49.70. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $4.42 billion, a price-to-earnings ratio of -12.92 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, equities research analysts expect that Definium Therapeutics will post -2.81 EPS for the current year.

Insider Buying and Selling at Definium Therapeutics

In related news, CEO Robert Barrow sold 29,208 shares of the firm's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $1,315,236.24. Following the completion of the transaction, the chief executive officer owned 1,098,246 shares of the company's stock, valued at approximately $49,454,017.38. This trade represents a 2.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Brandi Roberts sold 3,013 shares of the firm's stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the transaction, the chief financial officer directly owned 209,487 shares of the company's stock, valued at approximately $9,433,199.61. This trade represents a 1.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 48,096 shares of company stock worth $2,165,763. Company insiders own 2.40% of the company's stock.

Institutional Trading of Definium Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its position in Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock valued at $25,000 after purchasing an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company's stock valued at $55,000 after purchasing an additional 3,020 shares in the last quarter. Caxton Associates LLP acquired a new position in shares of Definium Therapeutics during the 3rd quarter worth approximately $126,000. Mercer Global Advisors Inc. ADV increased its position in shares of Definium Therapeutics by 10.5% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company's stock worth $259,000 after purchasing an additional 2,079 shares during the last quarter. Finally, Scientech Research LLC acquired a new position in shares of Definium Therapeutics during the 3rd quarter worth approximately $286,000. Institutional investors and hedge funds own 27.91% of the company's stock.

Definium Therapeutics News Summary

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its Phase 3 Voyage study showed DT120 produced a 5.4-point improvement in HAM-A anxiety scores versus placebo. The result represents the second positive late-stage study for the program and strengthens the case for regulatory approval and potential commercialization. Definium says LSD-based pill reduces anxiety in late-stage study
• Positive Sentiment: Coverage highlighted the positive Phase 3 results, with investor enthusiasm focused on DT120’s potential to address anxiety and disrupt the psychiatric-drug market. The company is also expected to provide additional data or updates ahead of a potential September 2026 catalyst. This LSD-Based Drug Just Scored Again. Definium Stock Soars.
• Positive Sentiment: Analysts raised their price targets following the trial update. Wells Fargo lifted its target from $68 to $72 and assigned an “overweight” rating, while Robert W. Baird raised its target from $57 to $75 with an “outperform” rating. Needham also increased its target from $50 to $66 and maintained a “buy” rating. These revisions imply substantial potential upside if DT120 succeeds commercially. Analyst price-target changes
• Neutral Sentiment: Trading in DFTX was temporarily halted for pending news on August 12, underscoring the market impact of the clinical announcement. Shares subsequently traded near the upper end of their 52-week range, reflecting heightened volatility and expectations.
• Negative Sentiment: HC Wainwright previously reduced its earnings forecasts across 2026-2030, including a deeper expected 2026 loss of $3.05 per share versus $2.10 previously and lower long-term estimates. Definium remains unprofitable, so valuation depends heavily on clinical execution, regulatory approval and DT120’s eventual commercial uptake.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source